Rapid depletion of plasma tryptophan: a review of studies and experimental methodology.
Evidence that the neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) plays a role in the pathophysiology of mood disorders has been accumulating over the past three decades. Recent studies on this neurotransmitter have extended across the spectrum of psychiatric disorder, suggesting a role for 5-HT in psychosis, aggression, eating disorders and addiction. However, much of the evidence has come from post-mortem examination of the brain or measures of peripheral rather than central 5-HT function. The technique of tryptophan depletion allows investigation of brain 5-HT function in living subjects by examining the behavioural responses to this pharmacological challenge. This review considers the current status of tryptophan depletion as an experimental technique and discusses the implications of findings both in affective disorders and in a range of other psychiatric syndromes. MEDLINE and PSYCHLIT searches were completed for the years 1966 to November 1996 using the key words 'serotonin', '5-hydroxytryptamine', 'tryptophan' and 'depletion'. In addition relevant journals were hand-searched for the period from 1980 to December 1996. Forty-four double-blind studies in humans and three clinical case reports were identified; these cover a range of psychiatric disorders including mood disorders and psychoses, anxiety and eating disorders and specific behaviours such as appetite, aggression and craving. The studies reviewed utilized a variety of differing methodologies reducing the extent to which results can be generalized. A series of studies in depressed patients (before and after treatment with antidepressants) and their first-degree relatives have shown the importance of an intact 5-HT system in the action of antidepressants and offer new insights into the biology of affective disorder. The mood change induced by tryptophan depletion may predict those patients likely to respond to 5-HT-specific drugs. Rapid tryptophan depletion has also been reported to exacerbate both panic and aggression in vulnerable individuals. Effects in other disorders are conflicting and further research is needed to clarify these findings.
Reilly
J G
JG
Division of Psychiatry, School of Neurosciences, University of Newcastle, Royal Victoria Infirmary, Newcastle Upon Tyne, UK.
McTavish
S F
SF
Young
A H
AH
D001714:Bipolar Disorder / Q000503:physiopathology; D004035:Diet Therapy; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D001523:Mental Disorders / Q000097:blood / Q000503:physiopathology* / Q000628:therapy*; D011619:Psychotropic Drugs / Q000627:therapeutic use*; D014364:Tryptophan / Q000097:blood / Q000172:deficiency* / Q000502:physiology*; D014365:Tryptophan Hydroxylase / Q000037:antagonists & inhibitors*
D004791:Enzyme Inhibitors; D011619:Psychotropic Drugs; D014364:Tryptophan; D014365:Tryptophan Hydroxylase